Transmedics Group Inc
NASDAQ:TMDX

Watchlist Manager
Transmedics Group Inc Logo
Transmedics Group Inc
NASDAQ:TMDX
Watchlist
Price: 136.51 USD -1.53% Market Closed
Market Cap: 4.7B USD

Transmedics Group Inc
Income from Continuing Operations

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Transmedics Group Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Transmedics Group Inc
NASDAQ:TMDX
Income from Continuing Operations
$91.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Income from Continuing Operations
$2.8B
CAGR 3-Years
62%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
Income from Continuing Operations
$2.9B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
10%
Abbott Laboratories
NYSE:ABT
Income from Continuing Operations
$14B
CAGR 3-Years
21%
CAGR 5-Years
33%
CAGR 10-Years
19%
IDEXX Laboratories Inc
NASDAQ:IDXX
Income from Continuing Operations
$1B
CAGR 3-Years
15%
CAGR 5-Years
16%
CAGR 10-Years
19%
Intuitive Surgical Inc
NASDAQ:ISRG
Income from Continuing Operations
$2.8B
CAGR 3-Years
26%
CAGR 5-Years
21%
CAGR 10-Years
18%
No Stocks Found

Transmedics Group Inc
Glance View

TransMedics Group Inc. emerged as a pioneering force within the medical technology sphere, aiming to revolutionize the organ transplant landscape. Founded with the bold vision of enhancing the viability of donor organs, TransMedics has developed the Organ Care System (OCS) — a portable, medical device designed to keep human organs alive and functioning outside of the body. The OCS effectively mimics the internal conditions of a human body, providing a nurturing environment that maintains organs in a near-living state. This innovation helps extend the time that organs can be viably transplanted, thereby increasing the success rates of transplants and offering a lifeline to individuals on long waiting lists. Monetizing this groundbreaking technology, TransMedics operates primarily through sales of its OCS products and related consumables, catering to well-established transplant centers worldwide. The company also taps into service agreements and training packages, ensuring that their clients can maximize the use and benefits of their products with the highest proficiency. In doing so, TransMedics not only empowers surgeons and hospitals to perform more successful transplants but also strengthens its position as a leading provider in a niche yet critical market. By addressing the challenges of organ preservation and transportation, TransMedics creates a compelling business model rooted in providing invaluable solutions for the healthcare industry and, ultimately, improving patient outcomes on a global scale.

TMDX Intrinsic Value
HIDDEN
Show

See Also

What is Transmedics Group Inc's Income from Continuing Operations?
Income from Continuing Operations
91.8m USD

Based on the financial report for Sep 30, 2025, Transmedics Group Inc's Income from Continuing Operations amounts to 91.8m USD.

What is Transmedics Group Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 1Y
181%

Over the last year, the Income from Continuing Operations growth was 181%.

Back to Top